This study has been performed on a total of 427 cases whose courses and prognosis were followed for one to six years, up in order to determine the most useful electrocardiographic criteria of the single two-step exercise test. The subjects were classified into the following five groups. Group 1: coronary-sclerotic patients (typical angina pectoris etc.) ; 41 cases, Group 2: patients with possible or undeniable coronary sclerosis; 120 cases, Group 3; patients not associated with cardiovascular diseases; 95 cases, Group 4: patients with NCA; 90 cases, and Group 5: normal healthy persons; 81 cases. The cases with definite ST·T change, bundle branch block and auricular fibrillation in resting electrocardiograms were not included for this study. The author would like to propose the new criteria which is better than the previous criteria. Considering Q-Q line as reference base line, the following change in ECG in any lead except Lead III and/or V2 was interpreted as abnormal response. (1) Any depression of ST or J of 1.5mm or more. (2) Ischemic ST depression of 0.5mm or more. (3) Junctional ST depression of 0.5mm or more, measuring at the point 0.04 sec. apart from J and accompanied by QX/QT ratio of 50 per cent or more and/or QT ratio 1.08 or more. (4) Inverted or isoelectric T waves. Utilizing above criteria, 53.1 per cent of abnormal response has been found in ST depression in the first or coronary-sclerotic group, that is, almost the same with the Master's classic criteria, while about 10 per cent in the third and fourth group, decreasing the number of false-positive incidence.
Pharmacological properties of amino-oxyacetic acid (AOAA), an inhibitor of γ-aminobutyric acid-α-ketoglutaric acid (GABA-AKG) transaminase, were examined with following results. 1. The acute intraperitoneal LD50 for AOAA were 286mg/kg in mice and 135mg/kg in rats. Behavioral changes seen following administration of AOAA were a decrease in spontaneous movements and a gradual sedation in all species tested. Vomiting was observed in cats, dogs and monkeys. In large doses, the clonic convulsion that seemed to be antagonized with pentobarbital was induced in various species of animal. 2. On the chronic toxicity test of rats (0.1-20mg/kg/day intraperitoneally for six months), the maximum tolerated daily dose was about 1mg/kg. This dose caused loss of weight, but did not kill any animal. The dose of 5mg/kg/day had no remarkable effects on blood pictures. Histopathological examination revealed pulmonary emphysema attributable to drug action. 3. The rabbit rectal temperature was lowered after subcutaneous or intravenous injection of AOAA (5-50 mg/kg) . 4. AOAA administered intravenously (10-120mg/kg) to pentobarbitalized dogs produced regularly a transitory depressor response accompanied with a marked respiratory excitation. This hypotensive effect was not reduced or abolished with following drugs: atropine, diphenhydramine, procain and papaverine given at pharmacologically active dose levels. Moreover, the deprssor action had remained during the pretreatment with the ganglionic blocking agents. AOAA did not modify the pressor response in blood pressure to occlusion of both carotid arteries, and its depressor action was not decreased with severance of bilateral cervical nerves, vagi, sympathetics and depressor nerves combined with carotid sinuses denervation. Depressor action of intra internal carotid arterial injection of AOAA was approximately ten times as potent as that of intravenous injection. Cardiac function was reduced both in the isolated rabbit heart and in the dog heart-lung preparation. AOAA showed the peripheral vasoconstriction in the rabbit ear vesseles and in the dog cross perfused hind quarter. 5. AOAA reduced both the tone and the amplitude of the spontaneously contracting rabbit ileum, while AOAA produced oxytocic action in the isolated rat uterus. 6. AOAA potentiated the responses both to direct and indirect stimulation in the isolated rat phrenic nerve-diaphragm preparation in large doses, and in very large doses reduced the responses both to direct and to indirect stimulation. Though positive effects were obtained, the concentrations used would be unlikely to be achieved in vivo and thus discontinued the experiments.
Twenty cases with the combined symptomes of hypertension, diabetes mellitus and arteriosclerosis were studied by means of fluorescein f undus photography using 10ml of 10 % fluorescein sodium solution. No side effects were observed either on pulse or on blood pressure, however xanthopsia occured in 9 cases and yellowish coloration of the skin developed in 18 cases, the incidence of either of them being higher than those used 5 ml of 5 % fluorescein sodium solution. The frequency of nausea or vomitting among side effects might be similar to or even less than that with the 5 % solution, if careful consideration was taken to the personal general health before the administation. Moreover, the time, during which fluorescent pattern produced with 10 % solution permitted to be photographed, was twice as much as that with the 5 % solution. The contrast between the fluorescent pattern and the background on the photograph was more distinct than that of the 5 % solution.
A 36-year-old female with acute erythroleukemia was described. In the initial stage megaloblastoid erythroblast were seen in the peripheral blood, and bone marrow were almost replaced by megaloblastoid cells. In the terminal stage myeloblasts increased in the bone marrow in place of erythroblasts, showing clinical picture of acute myelogenous leukemia. She had history of occupation in handling with benzol, however it was not clear whether benzol had related with the onset of this disease.
A case of subcutaneous rupture of bladder in a 31-year-old male, treated succesfully, was reported. Ninety nine cases of this disease were reported on the literature during 21 years since 1946 in Japan.
A 45-year-old male of hemochromatosis with anemia, liver enlargement, pigmentation of the skin and diabetes mellitus was described. Treatment with desferrioxamine, iron chelation substance, resulted in a marked improvement of clinical symptomes. Mechanism of action of desferrioxamine was discussed.